History

For more than two decades, Contura has been researching, developing and manufacturing hydrogel products across multiple therapeutic areas to provide doctors and veterinarians with a proven long-lasting, non-degradable bio-scaffold injectable.

By working with the scientific and clinical communities in Denmark and across the world, we research and develop 2.5% iPAAG* in areas where we believe a significant clinical need can be met with clinically meaningful results.

Our milestones

  • 2024

    Contura Vet acquires IMS Vet

  • 2023

    Contura begins expansion of current facility with the aim of fulfilling an expected demand of over 1 million in doses in 2026.

  • 2022

    Contura sets up US Animal Health Company, Contura Vet (USA) Inc to commercialise Arthramid Vet in the US.

    Contura expands offices in Copenhagen to create work space for over 100 employees.

    Results of randomised controlled trial comparing Arthrosamid with hyaluronic acid for treatment of knee osteoarthritis published.

  • 2021

    Contura sells Bulkamid to Axonics Modulation Technologies, Inc. and enters into an exclusive manufacturing and supply agreement.

  • 2020

    Approval of Bulkamid in the United States by FDA as Class 3 medical device for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency in adult women who have SUI or stress predominant mixed incontinence.

    Approval of Arthrosamid in Europe for the treatment of patients with knee osteoarthritis.

    Arthramid Vet approved as a drug in Australia.

    Arthramid Vet approved as a medical device in USA.

  • 2019

    Approval of Arthramid Vet in New Zealand as a novel drug for the treatment of lameness in horses.

    Publication in Clinical Orthopedics Advanced Research Journal, of the safety results for Arthrosamid for the treatment of knee osteoarthritis symptoms in a retrospective case series.

  • 2018

    Arthramid Vet licensed to Contura Vet for sale in the veterinary market.

  • 2017

    Contura’s manufacturing facility is granted EU GMP certificate.

    Worldwide rights to Mitem sold with distribution rights for Germany & Austria retained.

  • 2016

    Contura completes management buyout as part of plans to strategically focus on 2.5% iPAAG product range.

  • 2015

    2 year follow-up of Arthramid Vet clinical study reports with impressive results.

  • 2014

    Following impressive results in the clinical study of Arthramid Vet, development of Arthrosamid commences for the treatment of osteoarthritis in the knees of humans.

  • 2013

    Worldwide distribution rights for Bulkamid taken back from Ethicon and direct sale by Contura commences.

  • 2007

    Contura signs agreement with Johnson & Johnson granting Ethicon, its women’s health subsidiary, exclusive worldwide distribution rights for Bulkamid.

  • 2006

    Contura obtains ISO 13485 certificate, having demonstrated its ability to meet customer & regulatory requirements.

  • 2004

    Aquamid Reconstruction granted CE-mark for larger volume corrections, rhinoplasty and lipoatrophy.

  • 2003

    Bulkamid granted CE-mark for use in the treatment of female urinary incontinence.

  • 2001

    Aquamid granted CE-mark for use in facial augmentation.

  • 2000

    Contura established.

Contura International A/S

Contact us
Careers
About us
Team
Privacy notice

© copyright 2025 Contura International Ltd.

*2.5 iPAAG is an injectable polyacrylamide hydrogel known for its unique composition, comprising of 2.5% cross-linked polyacrylamide and 97.5% water.

Arthrosamid is a registered trademark of Contura International A/S.

Contura Vet is a registered trademark of Contura Vet Ltd.